Renal tubular epithelial cell self-injury through Fas/Fas ligand interaction promotes renal allograft injury

American Journal of Transplantation

Volumn 4, Issue 10, 2004, Pages 1583-1594

  Du, Caigan ^a,c,d   Jiang, Jifu ^a   Guan, Qiunong ^b   Yin, Ziqin ^b   Masterson, Mark ^b   Parbtani, Anwar ^a   Zhong, Robert ^a,b,d   Jevnikar, Anthony M ^a,b,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Apoptosis; Fas; FasL; Kidney; Transplantation; Tubular epithelial cell

Indexed keywords

CYTOKINE; DNA FRAGMENT; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; LIPOCORTIN 5; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DISEASE MODEL; ELIMINATION REACTION; EPITHELIUM CELL; GRAFT SURVIVAL; INHIBITION KINETICS; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TUBULE EPITHELIUM; LIGAND BINDING; MALE; MEMBRANE BINDING; MEMBRANE TRANSPORT; MONOLAYER CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SPLEEN CELL; STATISTICAL ANALYSIS; SURVIVAL;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; COCULTURE TECHNIQUES; CYTOKINES; DNA FRAGMENTATION; FAS LIGAND PROTEIN; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; MALE; MEMBRANE GLYCOPROTEINS; MICE; SPLEEN; UP-REGULATION;

EID: 4744367884     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00552.x     Document Type: Article

References (75)

1. Itoh N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-243.
2. Nagata S, Golstein P. The Fas death factor. Science 1995; 267; 1449-1456.
3. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
4. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 1994; 6: 1567-1574.
5. Suda T, Okazaki T, Naito Y et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154: 3806-3813.
6. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184: 429-440.
7. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995; 181: 1235-1238.
8. Boonstra JG, van der Woude FJ, Wever PC, Laterveer JC, Daha MR, van Kooten C. Expression and function of Fas (CD95) on human renal tubular epithelial cells. J Am Soc Nephrol 1997; 8: 1517-1524.
9. French LE, Hahne M, Viard I et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133: 335-343.
10. Lorz C, Ortiz A, Justo P et al. Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J Am Soc Nephrol 2000; 11: 1266-1277.
11. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995; 16: 569-574.
12. Thilenius AR, Braun K, Russell JH. Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants. Eur J Immunol 1997; 27: 1108-1114.
13. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
14. Hirata H, Takahashi A, Kobayashi S et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 1998; 187: 587-600.
15. Alderson MR, Lynch DH. Receptors and ligands that mediate activation-induced death of T cells. Springer Semin Immunopathol 1998; 19: 289-300.
16. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 186: 2045-2050.
17. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31-36.
18. Strasser A, O'Connor L. Fas ligand - caught between Scylla and Charybdis. Nat Med 1998; 4: 21-22.
19. Suzuki I, Fink PJ. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Exp Med 1998; 187: 123-128.
20. Tourneur L, Malassagne B, Batteux F et al. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts. J Immunol 2001; 167: 1338-1346.
21. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci U S A 1997; 94: 3943-3947.
22. Muruve DA, Nicolson AG, Manfro RC, Strom TB, Sukhatme VP, Libermann TA. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after Systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Hum Gene Ther 1997; 8: 955-963.
23. Suva DG, Petrovsky N, Socha L, Slattery R, Gatenby P, Charlton B. Mechanisms of accelerated immune-mediated diabetes resulting from islet beta cell expression of a Fas ligand transgene. J Immunol 2003; 170: 4996-5002.
24. Swenson KM, Ke B, Wang T et al. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 1998; 65: 155-160.
25. Christiaans MH, Overhof-de Roos R, Nieman F, Hooff JP, van den Berg-Loonen EM. Donor-specific antibodies after transplantation by flow cytometry: relative change in fluorescence ratio most sensitive risk factor for graft survival. Transplantation 1998; 65: 427-433.
26. Deckers JG, Boonstra JG, van der Kooij SW, Dana MR, van der Woude FJ. Tissue-specific characteristics of cytotoxic graft-infiltrating T cells during renal allograft rejection. Transplantation 1997; 64: 178-181.
27. Sirak J, Orosz CG, Wakely E, VanBuskirk AM. Alloreactive delayed-type hypersensitivity in graft recipients: complexity of responses and divergence from acute rejection. Transplantation 1997; 63; 1300-1307.
28. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422.
29. Bohle A, Oliveira de Cavalcant V, Laberke HG. Is there any tubular secretion of protein? Clin Nephrol 1988; 29; 28-34.
30. Risdon RA, Sloper JC, Wardener HED. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968; 2: 363-366.
31. Schainuck LI, Striker GE, Cutler RE, Benditt EP. Structural-functional correlations in renal disease. II. The correlations. Hum Pathol 1970; 1: 631-641.
32. Oberbauer R, Rohrmoser M, Regele H, Muhlbacher F, Mayer G. Apoptosis of tubular epithelial cells in donor kidney biopsies predicts early renal allograft function. J Am Soc Nephrol 1999; 10: 2006-2013.
33. Wever PC, Boonstra JG, Laterveer JC et al. Mechanisms of lymphocyte-mediated cytotoxicity in acute renal allograft rejection. Transplantation 1998; 66: 259-264.
34. Lin Y, Kirby JA, Clark K et al. Renal allograft rejection: induction and function of adhesion molecules on cultured epithelial cells. Clin Exp Immunol 1992; 90: 111-116.
35. Salaman JR. Monitoring of rejection in renal transplantation. Immunol Lett 1991; 29: 139-142.
36. Copin M, Noel C, Hazzan M et al. Diagnostic and predictive value of an immunohistochemical profile in asymptomatic acute rejection of renal allografts. Transpl Immunol 1995; 3: 229-239.
37. Ito H, Kasagi N, Shomori K, Osaki M, Adachi H. Apoptosis in the human allografted kidney. Analysis by terminal deoxynucleotidyl transferase-mediated DUTP-botin nick end labeling. Transplantation 1995; 60: 794-798.
38. Kato S, Akasaka Y, Kawamura S. Fas antigen expression and its relationship with apoptosis in transplanted kidney. Pathol Int 1997; 47: 230-237.
39. Porter CJ, Ronan JE, Cassidy MJ. Fas-Fas-ligand antigen expression and its relationship to increased apoptosis in acute renal transplant rejection. Transplantation 2000; 69: 1091-1094.
40. Laine J, Etelamaki P, Holmberg C, Dunkel L. Apoptotic cell death in human chronic renal allograft rejection. Transplantation 1997; 63: 101-105.
41. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature 1994; 370: 650-652.
42. Cohen JJ. Apoptosis: mechanisms of life and death in the immune system. J Allergy Clin Immunol 1999; 103: 548-554.
43. Chinnaiyan AM, O'Rourke K, Yu GL et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996; 274: 990-992.
44. Golstein P, Marguet D, Depraetere V. Homology between reaper and the cell death domains of Fas and TNFR1. Cell 1995; 81: 185-186.
45. Pan G, O'Rourke K, Chinnaiyan AM et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276; 111-113.
46. Albina JE, Cui S, Mateo RB, Reichner JS. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol 1993; 150: 5080-5085.
47. Davis MA, Ryan DH. Apoptosis in the kidney. Toxicol Pathol 1998; 26: 810-825.
48. Ortiz-Arduan A, Danoff TM, Kalluri R et al. Regulation of Fas and Fas ligand expression in cultured murine renal cells and in the kidney during endotoxemia. Am J Physiol 1996; 271; F1193-F1201.
49. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16: 39-43.
50. Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-976.
51. Singer GG, Carrera AC, Marshak-Rothstein A, Martinez C, Abbas AK. Apoptosis. Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr Opin Immunol 1994; 6: 913-920.
52. Wuthrich RP, Glimcher LH, Yui MA, Jevnikar AM, Dumas SE, Kelley VE. MHC class II, antigen presentation and tumor necrosis factor in renal epithelial cells. Kidney Int 1990; 37: 783-792.
53. Zhang Z, Schlachta C, Duff J, Stiller C, Grant D, Zhong R. Improved techniques for kidney transplantation in mice. Microsurgery 1995; 16: 103-109.
54. Mariani SM, Matiba B, Armandola EA, Krammer PH. The APO-1/Fas (CD95) receptor is expressed in homozygous MRL/lpr mice. Eur J Immunol 1994; 24: 311-3123.
55. Pagtalunan ME, Olson JL, Tilney NL, Meyer TW. Late consequences of acute ischemic injury to a solitary kidney. J Am Soc Nephrol 1999; 10: 366-373.
56. Ortiz A. Renal cell loss through cell suicide. Kidney Int 2000; 58: 2235-2236.
57. Ortiz A, Lorz C, Catalan MP, Justo P, Egido J. Role and regulation of apoptotic cell death in the kidney: Y2K update. Front Biosci 2000; 5: D735-D749.
58. Saikumar P, Dong Z, Mikhailov V, Denton M, Weinberg JM, Venkatachalam MA. Apoptosis: definition, mechanisms, and relevance to disease. Am J Med 1999; 107: 489-506.
59. Akasaka Y, Ishikawa Y, Kato S et al. Induction of Fas-mediated apoptosis in a human renal epithelial cell line by interferon-gamma: involvement of Fas-mediated apoptosis in acute renal rejection. Mod Pathol 1998; 11: 1107-1114.
60. Schneider P, Holler N, Bodmer JL et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-1213.
61. Mariani SM, Matiba B, Baumler C, Krammer PH. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloprotease. Eur J Immunol 1995; 25: 2303-2307.
62. Koide N, Marita K, Kato Y et al. Expression of Fas and Fas ligand on mouse renal tubular epithelial cells in the generalized shwartzman reaction and its relationship to apoptosis. Infect Immun 1999; 67: 4112-4118.
63. Conaldi PG, Biancone L, Bottelli A et al. HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. J Clin Invest 1998; 102: 2041-2049.
64. Schelling JR, Cleveland RP. Involvement of Fas-dependent apoptosis in renal tubular epithelial cell deletion in chronic renal failure. Kidney Int 1999; 56: 1313-1316.
65. + T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J Exp Med 1998; 188: 415-420.
66. Martin CA, Panja A. Cytokine regulation of human intestinal primary epithelial cell susceptibility to Fas-mediated apoptosis. Am J Physiol Gastrointest Liver Physiol 2002; 282: G92-G104.
67. Rathbun RK, Christianson TA, Faulkner GR et al. Interferon-gamma-induced apoptotic responses of Fanconi anemia group C hematopoietic progenitor cells involve caspase 8-dependent activation of caspase 3 family members. Blood 2000; 96: 4204-4211.
68. Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley VR. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas (lpr) mice. J Immunol 1998; 161: 494-503.
69. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255-260.
70. Tschopp J, Martinen F, Hofmann K. Apoptosis: Silencing the death receptors. Curr Biol 1999; 9: R381-R384.
71. Tan KH, Hunziker W. Compartmentalization of Fas and Fas ligand may prevent auto- or paracrine apoptosis in epithelial cells. Exp Cell Res 2003; 284: 283-290.
72. Hsu PN, Lin HH, Tu CF et al. Expression of human Fas ligand on mouse beta islet cells does not induce insulitis but is insufficient to confer immune privilege for islet grafts. J Biomed Sci 2001; 8: 262-269.
73. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632.
74. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99: 396-402.
75. Kang SM, Schneider DB, Lin Z et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738-743.